The International Journal of Neuropsychopharmacology 2025

14 papers
The 2025 edition of The International Journal of Neuropsychopharmacology comprises 14 papers covering clinical psychiatry, neurobiology, and digital health. A primary focus involves the pharmacological treatment of Major Depressive Disorder, with specific studies analyzing the efficacy and long-term safety of lumateperone through pooled Phase 3 trials and open-label extension studies. Research also addresses the management of tardive dyskinesia in Southeast Asia and cognitive deficits, such as decision-making confidence in obsessive-compulsive disorder. Notable research directions include the application of digital phenotyping and artificial intelligence for early dementia detection and the use of network analysis to study psychosomatic symptoms in type 2 diabetes. The edition also explores biological aging indicators in stress-related disorders and the impact of COVID-19 on white matter microstructural alterations in both healthy and depressed populations. Frequent contributors to this year’s research include Yonggui Yuan, Chenguang Jiang, Gang Chen, and Linlin You. The volume reflects a trend toward integrating multimodal MRI studies and lifestyle interventions into psychiatric practice.

Top Research Directions

The 4 research directions with The International Journal of Neuropsychopharmacology 2025 papers, ranked by paper count, next to 2024. Share is the fraction of the edition’s papers in the direction.

#Direction20252024Share 2025Share 20242024 rank
1Controlling False Positives in Multiple Hypothesis Testing107.1%0.0%—
2Enzyme Linked Immunosorbent Assays for Biomarker Quantification107.1%0.0%—
3Medication Naive Cohorts for Unconfounded Biomarker Discovery107.1%0.0%—
4Pharmacological Confounding in Clinical Biomarker Research107.1%0.0%—

Download all directions as CSV

Institutions

Institutions credited by The International Journal of Neuropsychopharmacology 2025 papers: a paper credits every institution named in its affiliations, once. 3 institutions share 1 credited papers.

#InstitutionPapersShare20242024 rank
100mj90n62 1100.0%0—
2Peking University 1100.0%0—
3Shanghai Jiao Tong University 1100.0%0—

Download all institutions as CSV

About this data

Papers. The International Journal of Neuropsychopharmacology 2025 lists 14 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2024 use shares, since the edition went from 3 to 14 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 14 papers (7.1%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “The International Journal of Neuropsychopharmacology 2025”, https://lacuna.tiptreesystems.com/venue/the-international-journal-of-neuropsychopharmacology/2025.

Top Authors

AuthorPapers
Christopher Li Hsian Chen2
Kerrie Mengersen1
Wenhao Jiang1

Papers

Title
188. DEVELOPMENT OF METABOLOMIC BIOMARKER SIGNATURES AND DIAGNOSTIC MODELS FOR MAJOR DEPRESSIVE DISORDER USING MULTIPLE SUPERVISED LEARNING METHODS
299. SENSORS IN-HOME FOR ELDER WELLBEING (SINEW): DIGITAL PHENOTYPING AND ARTIFICIAL INTELLIGENCE FOR EARLY DETECTION OF DEMENTIA
608. INVESTIGATING ASSOCIATIONS BETWEEN BDNF, CORTISOL, AND COGNITIVE PERFORMANCE DURING PSYCHOSOCIAL AND HEAT STRESS
610. LONG-TERM ADJUNCTIVE LUMATEPERONE TREATMENT IN MAJOR DEPRESSIVE DISORDER: RESULTS FROM A SIX-MONTH OPEN-LABEL EXTENSION STUDY
612. EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: A POOLED ANALYSIS OF PHASE 3 RANDOMIZED CONTROLLED TRIALS
640. BIOLOGICAL AGING INDICATORS IN STRESS-RELATED DISORDERS: A (NEURO)BIOLOGICAL PERSPECTIVE ON LIFESTYLE INTERVENTIONS IN PSYCHIATRIC PRACTICE
CHANGES IN CORE DEPRESSIVE SYMPTOMS OVER TIME IN PERIPARTUM WOMEN: A NETWORK ANALYSIS
CONSENSUS RECOMMENDATIONS ON THE RECOGNITION, ASSESSMENT, AND MANAGEMENT OF TARDIVE DYSKINESIA IN COUNTRIES FROM SOUTHEAST ASIA
IMPACT OF COVID-19 INFECTION ON WHITE MATTER MICROSTRUCTURAL ALTERATIONS IN HEALTHY POPULATION AND MAJOR DEPRESSIVE DISORDER: A MULTIMODAL MRI STUDY
PRACTICAL GUIDELINES ON THE USE OF CARIPRAZINE IN BIPOLAR 1 DISORDER: EXPERT CONSENSUS FROM SOUTHEAST ASIA
PSYCHOSOMATIC SYMPTOMS IN TYPE 2 DIABETES PATIENTS: A NETWORK ANALYSIS
Sedative and hypnotic effects of nuciferine: enhancing rodent sleep via serotonergic system modulation
Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia
THE DEFICITS OF DECISION-MAKING CONFIDENCE IN OBSESSIVE- COMPULSIVE DISORDER